Phase 3
Completed N=316
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Motion Sickness
Source: ClinicalTrials.gov NCT05903924 ↗
Enrolled (actual)
316
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants
◆ Published Evidence
Not yet cited
0citations
Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.
Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
Linked Publications
-
Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevention of Vomiting Measured by Vomiting Assessment (VA) |
11; 19; 40 | — |
Eligibility Criteria
Inclusion Criteria
- History of motion sickness
- Age 18-75
Exclusion Criteria
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Data sourced from ClinicalTrials.gov (NCT05903924) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.